Genomma Lab Internacional, S.A.B. de C.V. GNMLF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.51% | 10.51% | -5.56% | -11.46% | -11.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.51% | 10.51% | -5.56% | -11.46% | -11.18% |
| Cost of Revenue | 2.45% | 8.68% | -0.25% | -10.48% | -9.90% |
| Gross Profit | 7.27% | 11.59% | -8.68% | -12.00% | -11.89% |
| SG&A Expenses | 12.20% | 14.70% | -13.34% | -9.27% | -13.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 82.66% | -43.94% | 593.71% | -273.58% | -272.06% |
| Total Operating Expenses | 8.34% | 11.83% | -5.35% | -11.03% | -12.19% |
| Operating Income | -4.49% | 5.77% | -6.41% | -12.96% | -7.39% |
| Income Before Tax | 7.76% | 6.74% | 15.59% | -33.84% | -41.62% |
| Income Tax Expenses | -10.93% | -14.22% | 54.41% | -35.29% | -15.48% |
| Earnings from Continuing Operations | 18.39% | 15.25% | -2.58% | -33.24% | -50.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.39% | 15.25% | 309.65% | -33.24% | -50.35% |
| EBIT | -4.49% | 5.77% | -6.41% | -12.96% | -7.39% |
| EBITDA | -3.29% | 6.03% | -7.29% | -11.35% | -4.91% |
| EPS Basic | 16.49% | 16.00% | 311.63% | -36.22% | -51.67% |
| Normalized Basic EPS | 5.98% | 7.76% | 19.76% | -36.70% | -43.21% |
| EPS Diluted | 16.49% | 16.00% | 311.63% | -36.22% | -51.67% |
| Normalized Diluted EPS | 5.98% | 7.76% | 19.76% | -36.70% | -43.21% |
| Average Basic Shares Outstanding | 1.59% | -0.82% | -0.84% | 4.62% | 2.90% |
| Average Diluted Shares Outstanding | 1.59% | -0.82% | -0.84% | 4.62% | 2.90% |
| Dividend Per Share | -- | 16.33% | -72.68% | -- | -- |
| Payout Ratio | -- | 0.01% | 1.56% | 2.04% | -1.00% |